{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mediastinal+Large+B-cell+Lymphoma&page=3",
    "query": {
      "condition": "Mediastinal Large B-cell Lymphoma",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 111,
    "total_pages": 12,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mediastinal+Large+B-cell+Lymphoma&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mediastinal+Large+B-cell+Lymphoma&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T07:01:54.368Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05202782",
      "title": "Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation",
        "EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
        "High Grade B-Cell Lymphoma, Not Otherwise Specified",
        "Large B-Cell Lymphoma With IRF4 Rearrangement",
        "Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type",
        "Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma",
        "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
        "Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "Recurrent Intravascular Large B-Cell Lymphoma",
        "Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma",
        "Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma",
        "Recurrent Transformed B-Cell Non-Hodgkin Lymphoma",
        "Refractory Aggressive B-Cell Non-Hodgkin Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
        "Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "Refractory Intravascular Large B-Cell Lymphoma",
        "Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma",
        "Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma",
        "Refractory Transformed B-Cell Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Chimeric Antigen Receptor T-Cell Therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Zanubrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2022-03-21",
      "completion_date": "2029-10-09",
      "has_results": false,
      "last_update_posted_date": "2024-10-16",
      "last_synced_at": "2026-10-07T07:01:54.368Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05202782"
    },
    {
      "nct_id": "NCT04409314",
      "title": "Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Recurrent Aggressive Non-Hodgkin Lymphoma",
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Recurrent High Grade B-Cell Lymphoma",
        "Recurrent Malignant Neoplasm",
        "Recurrent Plasma Cell Myeloma",
        "Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma",
        "Refractory Aggressive Non-Hodgkin Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Refractory High Grade B-Cell Lymphoma",
        "Refractory Malignant Neoplasm",
        "Refractory Plasma Cell Myeloma",
        "Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Fluorine F 18-fluoroazomycin Arabinoside",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2020-04-16",
      "completion_date": "2023-08-09",
      "has_results": false,
      "last_update_posted_date": "2023-08-21",
      "last_synced_at": "2026-10-07T07:01:54.368Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04409314"
    },
    {
      "nct_id": "NCT04745559",
      "title": "Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large-Cell Lymphoma",
        "Primary Mediastinal Large B-Cell Lymphoma (PMBCL)",
        "Transformed Follicular Lymphoma (TFL)",
        "High-grade B-cell Lymphoma (HGBCL)",
        "Follicular Lymphoma"
      ],
      "interventions": [
        {
          "name": "Pneumococcal conjugate vaccine (PCV13)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CD19 targeted CAR T Cell Therapy",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2021-02-18",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-01-29",
      "last_synced_at": "2026-10-07T07:01:54.368Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04745559"
    },
    {
      "nct_id": "NCT03019666",
      "title": "Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Non-Hodgkin Lymphoma",
        "Diffuse Large B Cell Lymphoma",
        "Mantle-Cell Lymphoma",
        "Follicular Lymphoma",
        "Indolent B Cell Lymphoma",
        "Primary Mediastinal Lymphoma",
        "Lymphoplasmacytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 39,
      "start_date": "2017-10-18",
      "completion_date": "2022-08-15",
      "has_results": false,
      "last_update_posted_date": "2022-11-04",
      "last_synced_at": "2026-10-07T07:01:54.368Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03019666"
    },
    {
      "nct_id": "NCT04875195",
      "title": "A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hodgkin's Lymphoma",
        "Primary Mediastinal Large B-cell Lymphoma (PMBCL)"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2021-06-07",
      "completion_date": "2025-10-13",
      "has_results": true,
      "last_update_posted_date": "2025-10-29",
      "last_synced_at": "2026-10-07T07:01:54.368Z",
      "location_count": 3,
      "location_summary": "Torrance, California • New Orleans, Louisiana • Annapolis, Maryland",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Annapolis",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04875195"
    },
    {
      "nct_id": "NCT00361621",
      "title": "Ph II CHOP+Velcade in Mediastinal LBCL",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma"
      ],
      "interventions": [
        {
          "name": "bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2006-07",
      "completion_date": "2008-05",
      "has_results": false,
      "last_update_posted_date": "2012-12-03",
      "last_synced_at": "2026-10-07T07:01:54.368Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00361621"
    },
    {
      "nct_id": "NCT06544265",
      "title": "SynKIR-310 for Relapsed/Refractory B-NHL",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "B Cell Lymphoma",
        "NHL, Adult",
        "Mantle Cell Lymphoma",
        "Relapsed Non-Hodgkin Lymphoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Aggressive B-Cell Non-Hodgkin Lymphoma",
        "Indolent B-Cell Non-Hodgkin Lymphoma",
        "Follicular Lymphoma",
        "Marginal Zone Lymphoma",
        "DLBCL - Diffuse Large B Cell Lymphoma",
        "HGBL With MYC and BCL2 and/or BCL6 Rearrangements",
        "High-grade B-cell Lymphoma",
        "Diffuse Large B Cell Lymphoma",
        "Large B-cell Lymphoma",
        "T-Cell/Histiocyte Rich Lymphoma",
        "Non-hodgkin Lymphoma,B Cell",
        "Primary Mediastinal Large B-cell Lymphoma (PMBCL)",
        "Epstein-Barr Virus Positive DLBCL, Nos",
        "Follicular Lymphoma Grade 3B",
        "DLBCL (Diffuse Large B-Cell Lymphoma) Associated With Chronic Inflammation",
        "High Grade B-Cell Lymphoma, Not Otherwise Specified",
        "Follicular Lymphoma Grade 3",
        "Marginal Zone Splenic Lymphoma",
        "DLBCL",
        "Waldenstrom Macroglobulinemia",
        "Waldenstrom Macroglobulinaemia"
      ],
      "interventions": [
        {
          "name": "SynKIR-310",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Verismo Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2024-11-01",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-14",
      "last_synced_at": "2026-10-07T07:01:54.368Z",
      "location_count": 5,
      "location_summary": "Denver, Colorado • Atlanta, Georgia • Fairway, Kansas + 2 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Fairway",
          "state": "Kansas"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06544265"
    },
    {
      "nct_id": "NCT03153462",
      "title": "Axicabtagene Ciloleucel Expanded Access Study",
      "overall_status": "APPROVED_FOR_MARKETING",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Relapsed/Refractory Diffuse Large B Cell Lymphoma",
        "Relapsed/Refractory Primary Mediastinal B Cell Lymphoma",
        "Relapsed/Refractory Transformed Follicular Lymphoma",
        "Relapsed/Refractory High-Grade B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Axicabtagene Ciloleucel",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Kite, A Gilead Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2023-11-08",
      "last_synced_at": "2026-10-07T07:01:54.368Z",
      "location_count": 15,
      "location_summary": "Duarte, California • Stanford, California • Miami, Florida + 12 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03153462"
    },
    {
      "nct_id": "NCT05255601",
      "title": "A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin",
        "Hodgkin Disease"
      ],
      "interventions": [
        {
          "name": "Relatlimab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "Up to 30 Years"
      },
      "enrollment_count": 5,
      "start_date": "2022-09-13",
      "completion_date": "2025-12-03",
      "has_results": true,
      "last_update_posted_date": "2026-06-26",
      "last_synced_at": "2026-10-07T07:01:54.368Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05255601"
    },
    {
      "nct_id": "NCT06209619",
      "title": "CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "B-Cell Non-Hodgkin Lymphoma-Recurrent",
        "Diffuse Large B-Cell Lymphoma-Recurrent",
        "Follicular Lymphoma-Recurrent",
        "High Grade B-Cell Lymphoma-Recurrent",
        "Primary Mediastinal Large B-Cell Lymphoma-Recurrent",
        "Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent",
        "B-Cell Non-Hodgkin Lymphoma-Refractory",
        "Diffuse Large B-Cell Lymphoma-Refractory",
        "Follicular Lymphoma-Refractory",
        "High Grade B-Cell Lymphoma-Refractory",
        "Primary Mediastinal Large B-Cell Lymphoma-Refractory",
        "Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Refractory"
      ],
      "interventions": [
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Golcadomide",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Nathan Denlinger",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2024-01-29",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-10-07T07:01:54.368Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06209619"
    }
  ]
}